Plain-English translation of NCT07461532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing apixaban, a blood-thinning medication, to see if it can help dissolve blood clots that form in the portal vein (a major blood vessel in the liver) after spleen removal surgery. The study focuses on people whose clots appeared more than one year after their operation, which is unusual and suggests a different underlying cause than typical post-surgery clots.
Blood clots in the liver's portal vein can be serious and limit treatment options, but it's unclear whether this medication works well for clots that appear this long after surgery. This trial aims to answer that question so doctors have better tools to treat this rare but important complication.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily. Every three months, you'll have imaging tests (ultrasound or CT scans) to see if the blood clot is improving. If the treatment is working, you'll continue taking the medication and returning for these regular check-ups. The study involves about 20 participants total.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Northern Jiangsu People's Hospital
Enrollment target
~20 participants
Started
April 2026
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guo-Qing Jiang, MD
Clinical Medical College, Yangzhou University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.